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Abstract
Background: Family history and twins studies suggest an inherited component to ischemic stroke
risk. Candidate gene association studies have been performed but have limited capacity to identify
novel risk factor genes. The Siblings With Ischemic Stroke Study (SWISS) aims to conduct a
genome-wide scan in sibling pairs concordant or discordant for ischemic stroke to identify novel
genetic risk factors through linkage analysis.
Methods: Screening at multiple clinical centers identifies patients (probands) with radiographically
confirmed ischemic stroke and a family history of at least 1 living full sibling with stroke. After giving
informed consent, without violating privacy among other family members, the proband invites
siblings concordant and discordant for stroke to participate. Siblings then contact the study
coordinating center. The diagnosis of ischemic stroke in potentially concordant siblings is
confirmed by systematic centralized review of medical records. The stroke-free status of
potentially discordant siblings is confirmed by validated structured telephone interview. Blood
samples for DNA analysis are taken from concordant sibling pairs and, if applicable, from 1
discordant sibling. Epstein-Barr virus-transformed lymphoblastoid cell lines are created, and a scan
of the human genome is planned.
Discussion: Conducting adequately powered genomics studies of stroke in humans is challenging
because of the heterogeneity of the stroke phenotype and the difficulty of obtaining DNA samples
from clinically well-characterized members of a cohort of stroke pedigrees. The multicentered
design of this study is intended to efficiently assemble a cohort of ischemic stroke pedigrees
without invoking community consent or using cold-calling of pedigree members.
Background
Stroke is the third leading cause of death in adults. The 2
basic types of stroke are ischemic stroke and hemorrhagic
stroke. In ischemic stroke, the most common type, a pro-
found disturbance of focal cerebral blood flow leads to ir-
reversible parenchymal injury. The Siblings With Ischemic
Stroke Study (SWISS) is a multicenter affected sibling pair
study with the aim of identifying chromosomal regions
linked to ischemic stroke by using genome-wide scanning.
Family history and twins studies support the existence of
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genetic susceptibility to stroke [1–4]. Mendelian disorders
known to be associated with an increased risk of stroke in-
clude hemoglobinopathies, dyslipoproteinemias, and car-
dioembolic disorders [5]. Most known Mendelian stroke
disorders present in infancy, childhood, or young adult-
hood and collectively represent only a small proportion of
all stroke cases. Several of these Mendelian disorders were
recognized as unique genetic diseases because of striking
phenotypic features, such as corneal opacities and angiok-
eratomas of the skin in Fabry disease.
Defining the genetic basis for stroke syndromes that lack
striking phenotypic features is a more difficult task. Mod-
el-dependent linkage analysis has been used in large ped-
igrees with diseases such as cerebral autosomal dominant
arteriopathy with subcortical infarcts and leukoencepha-
lopathy (CADASIL) [6–9]. However, traditional linkage
analysis is unlikely to be the most expedient method of
finding novel stroke-susceptibility genes when carrier sta-
tus cannot be defined on the basis of distinctive clinical,
radiographic, or laboratory features.
One popular method of identifying genetic risk factors
has been the candidate gene association study, in which
investigators compare rates of one or more variant poly-
morphisms of a candidate gene among stroke cases and
stroke-free controls. Identifying risk factors depends on
selecting the right candidate genes, a daunting task be-
cause the human genome harbors about 30,000 genes. A
candidate gene is usually selected because the gene prod-
uct might relate to pathogenesis of disease.
Numerous studies have used a candidate gene approach
to define genetic risk factors for stroke, but so far results
for several categories of candidate genes have been nega-
tive or conflicting. For example, because about 80% of
strokes are caused by thrombotic occlusion of a blood ves-
sel, genes related to the coagulation system would seem
logical candidates for susceptibility to stroke. However,
despite association of the factor V G1691A (factor V Lei-
den) and prothrombin (factor II) G20210A mutations
with venous thromboembolism and myocardial infarc-
tion [10,11], neither mutation is strongly associated with
risk of stroke [12–18]. Although a study of British adults
found elevated levels of serum homocysteine to be associ-
ated with an increased risk of stroke [19], a case-control
study of a common polymorphism (methylenetetrahy-
drofolate reductase [MTHFR] T677C) that results in in-
creased serum homocysteine concentrations found no
difference between patients with stroke and controls in ei-
ther genotype or allele frequency [20]. Because antiplate-
let agents with different mechanisms of action can bring
about significant reductions in stroke risk, several platelet
receptor genes have been tested as candidate stroke sus-
ceptibility genes [21,22]. To date, however, no compelling
evidence for an association between any platelet receptor
gene polymorphism and risk of stroke has been found.
Conflicting results have been reported from studies on the
stroke risk factor status of genes related to myocardial inf-
arction or arterial disease, such as specific genotypes of the
genes for angiotensin 1-converting enzyme (ACE) [23–
26] or apolipoprotein [27–34]. Potential confounding
factors include the effects of comorbidity and differential
mortality rates [34,35]. Although the degree of stenosis of
the cervical internal carotid arteries in symptomatic pa-
tients correlates with risk of ipsilateral stroke [36], no clear
conclusions can be drawn from attempts to relate carotid
artery disease to specific genotypes (for example, of the
paraoxonase gene PON, which is thought to protect low-
density lipoprotein against oxidative modification [37],
or of the endothelial nitric oxide synthase gene [38]).
Thus, results of the candidate gene approach have so far
failed to define genetic risk factors for stroke. Further-
more, if important functional mutations should arise in
noncoding regions without significant disequilibrium
with the site of a screened polymorphism, the association
analysis may exclude the true disease susceptibility locus.
A genome-wide scanning approach in sibling pairs may
expedite discovery of novel risk factor genes. The basic
goal of the genome-wide scan with microsatellite markers
is to identify chromosomal regions linked to a disease
phenotype by determining whether polymorphisms in
the microsatellite markers segregate with disease within a
cohort of pedigrees. Microsatellites are not functional;
they are noncoding regions of DNA that allow identifica-
tion of chromosomal regions held in common by mem-
bers of a pedigree.
The collection of sibling pairs and analysis of mean pro-
portion of alleles shared that are identical (by descent or
state) by use of a highly polymorphic panel of genetic
markers has come to be a standard protocol for detecting
linkage of a disease susceptibility locus to a chromosomal
region. The technique has been applied to a broad range
of other disorders, including multiple sclerosis [39–42],
Alzheimer disease [43–45], type 1 diabetes [46], type 2 di-
abetes [47], asthma [48], and systemic lupus erythemato-
sus [49]. The use of such linkage-mapping strategies offers
the advantage of model-independence, computational
speed, and systematic identification of novel loci [39].
Thus, linkage analysis using a genome-wide scan may
yield positive results more efficiently than testing candi-
date genes a few at a time. However, we do not consider
these approaches to be mutually exclusive. Genome-wide
linkage analysis may guide selective candidate gene evalu-
ations within regions of importance. The goal of SWISS isBMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/1
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to help to identify the chromosomal regions that should
be searched for candidate genes.
The paucity of genome-wide scanning studies in the
stroke literature to date is mainly due to theoretical and
logistical factors that make such studies difficult to design.
Ischemic stroke itself represents a heterogeneous pheno-
type. Various systems have been used to classify subtypes
of ischemic stroke [50]. For example, the Trial of
ORG10172 in Acute Stroke Treatment (TOAST) investiga-
tors classified stroke into large-artery atherosclerosis, car-
dioembolism, small-vessel occlusion, stroke of other
etiology, and stroke of undetermined etiology [51]. Un-
certainty exists as to whether the clinical heterogeneity of
the ischemic stroke phenotype relates to heterogeneity in
genetic risk factors.
Logistically, the collection of a large number of sibling
pairs concordant for stroke is a daunting task. Stroke af-
fects an elderly population and carries a modest case fatal-
ity rate. Patients may be rendered incompetent to consent
to a genetics study by the stroke itself. Often, members of
a sibship are separated by large geographical distances. In
a preliminary study, we found that, whereas 1 in 10 pa-
tients with stroke report having a living affected sibling,
only 1 in 50 had an affected sibling living in the same city
as the proband [52].
SWISS is designed to overcome these hurdles as far as pos-
sible. The purpose of this paper is to describe the SWISS
protocol in detail.
Research Design and Methods
Aim
The aim of SWISS is to test the hypothesis that the human
genome contains chromosomal regions associated with
ischemic stroke by means of genome-wide scanning in
DNA samples collected from 300 sibling pairs concordant
for ischemic stroke and from 200 discordant siblings.
Definition of ischemic stroke and its subtypes
Stroke is defined according to World Health Organization
criteria [53] as rapidly developing signs of a focal or global
disturbance of cerebral function, with symptoms lasting
24 hours or longer or leading to death with no apparent
cause other than vascular origin. Patients are classified as
having an ischemic stroke if they had computed tomo-
graphic or magnetic resonance imaging of the brain done
within 7 days of onset of symptoms that either identified
the symptomatic cerebral infarct or failed to identify an al-
ternative cause of the symptoms. Classification of strokes
into subtypes is done according to the validated TOAST
diagnostic criteria [51]. Subtype diagnosis is made on the
basis of available and relevant information obtained up to
3 months after the stroke, because initial subtype diagno-
sis varies from final diagnosis in approximately one-third
of cases [54].
Study population
Three groups of subjects will be studied: probands, con-
cordant siblings, and discordant siblings (Fig. 1).
Probands
Probands are adult men and women who 1) have a diag-
nosis of at least 1 ischemic stroke confirmed by the study
neurologist, 2) report having at least 1 living full sibling
with a history of stroke, and 3) have attained their 18th
birthday at the time of enrollment in the study. If
probands have had more than one ischemic stroke, the
most recent is the proband index stroke. Probands are not
excluded from the study for radiographic evidence of he-
morrhagic transformation of an ischemic stroke.
Probands are not enrolled if any of the following condi-
tions apply: 1) The index stroke is presumed to be iatro-
genic – that is, onset of symptoms occurred within 48
hours after an invasive cerebrovascular or cardiovascular
procedure, such as coronary artery bypass grafting, a cath-
eter-based procedure on carotid or coronary arteries, ca-
rotid endarterectomy, heart valve surgery, or thoracic or
thoracoabdominal aortic aneurysm repair. 2) The index
stroke is presumed due to vasospasm after nontraumatic
subarachnoid hemorrhage – that is, the onset of symp-
toms occurred within 60 days after the onset of a nontrau-
matic subarachnoid hemorrhage. Virtually all delayed
cerebral ischemia occurs 5 to 21 days after subarachnoid
hemorrhage [55,56]. 3) The index stroke is presumed due
to an autoimmune condition – that is, the patient has a
history of brain-biopsy-proven central nervous system
vasculitis. 4) The patient is known to have any of the fol-
lowing single-gene or mitochondrial disorders recognized
by a distinctive phenotype: CADASIL, Fabry disease, ho-
Figure 1
Sample study pedigree for the Siblings With Ischemic Stroke
Study (SWISS). Solid symbols indicate ischemic stroke; CS,
concordant sibling; and DS, discordant sibling.BMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/1
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mocystinuria, mitochondrial encephalopathy with lactic
acidosis and stroke-like episodes (MELAS), or sickle cell
anemia. We excluded probands with these disorders be-
cause their enrollment might confound the genome scan
for novel risk factors. 5) The patient had a mechanical aor-
tic valve or a mechanical mitral valve at the time of index
stroke onset. We chose this criterion because of the high
likelihood that ischemic stroke is iatrogenic in such pa-
tients. 6) The patient had untreated or actively treated bac-
terial endocarditis at the time of index stroke onset.
Concordant Siblings
To be enrolled as a concordant sibling, the subject must
have a full sibling enrolled as a proband in SWISS. Other
eligibility criteria for concordant siblings are identical to
those of probands. Both proband and concordant sibling
must be at least 18 years old at the time of enrollment and
both must meet the same definition of ischemic stroke.
For concordant siblings, the diagnosis of ischemic stroke
is verified retrospectively by the Stroke Verification Com-
mittee (SVC). This is a central, genotype-blinded commit-
tee of study-appointed neurologists (Appendix), which
adjudicates the diagnosis and subtype of ischemic stroke
for concordant siblings, using standardized, prespecified
criteria. Although the subtype of the sibling's index
ischemic stroke is determined, enrollment is not restricted
to siblings with the same ischemic stroke subtype as
probands.
Discordant Siblings
Inclusion criteria for discordant siblings are as follows: 1)
The subject has attained his or her 18th birthday at the
time of enrollment. 2) The subject has 2 or more full sib-
lings who each have had an ischemic stroke and who are
participating in the study. 3) The subject reports having
no medical history of stroke or transient ischemic attack
(TIA) and denies ever having had symptoms of stroke. Be-
cause a SWISS proband might erroneously believe that a
sibling never had a stroke, discordance is considered veri-
fied only if the sibling can be contacted for a structured
telephone interview and gives negative answers to all 8
items on the Questionnaire for Verifying Stroke-Free Sta-
tus (QVSFS) (Table 1) [57,58]. Discordant siblings are ex-
cluded if they are deemed unreliable historians in the
opinion of the interviewer administering the QVSFS on
the basis of global impression of moderate or severe im-
pairment of speech, language, hearing, or memory.
Recruitment goals
We aim to enroll at least 300 concordant sibling pairs
(300 probands plus 300 concordant siblings) and 200
discordant siblings (800 total study subjects). Because it is
likely that not all concordant siblings will actually partic-
ipate, more than 300 probands will be enrolled to obtain
DNA from 300 concordant sibling pairs.
Study procedures
Table 2 summarizes the procedures for enrolling subjects
into the study and obtaining blood samples for DNA anal-
ysis.
Phase I. Enrolling Probands and Recruiting Siblings
Screening and enrollment will take place at 50 participat-
ing centers in the United States and Canada (Appendix).
At each center, a study neurologist screens all patients
with a possible diagnosis of ischemic stroke to identify
potential SWISS probands, orders or reviews medical tests
pertinent to the diagnosis and subtyping of ischemic
stroke as part of routine clinical practice, and makes a new
diagnosis or confirms a previous diagnosis of ischemic
stroke in a potential proband. A certified study neurolo-
gist classifies the final subtype of the index stroke accord-
ing to TOAST criteria [51]. To obtain certification the
neurologist reads the original manuscript describing the
TOAST classification system and scores various patients
presented in a series of stanardized clinical vignettes ac-
cording to TOAST criteria. The scores are compared with
reference values generated by a consensus of the SVC. The
investigator receives feedback on any deviations from ref-
erence values and is required to review the TOAST classifi-
cation system and retake the test.
The local coordinator or study neurologist conducts a
face-to-face interview with patients who meet enrollment
criteria to obtain their medical history and to explain the
Table 1: Questionnaire for Verifying Stroke-Free Status 
(QVSFS)
Medical history
Were you ever told by a physician that you had a stroke?
Were you ever told by a physician that you had a TIA, ministroke, or 
transient ischemic attack?
Review of symptoms
Have you ever had sudden, painless weakness on one side of your 
body?
Have you ever had sudden numbness or a dead feeling on one side of 
your body?
Have you ever had sudden, painless loss of vision in one or both eyes?
Have you ever suddenly lost one half of your vision?
Have you ever suddenly lost the ability to understand what people 
were saying?
Have you ever suddenly lost the ability to express yourself verbally or 
in writing?
From Meschia et al. [57]. By permission of the American Heart Asso-
ciation.BMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/1
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study. If patients agree to participate in the study, they
sign and date 2 copies of the informed consent form, re-
taining 1 copy for themselves. The local coordinator com-
pletes the proband case report forms (CRFs), assigns a
SWISS study number to the proband, forwards the
proband CRFs to the Clinical Coordinating Center, and
gives the proband (or surrogate) a set of study invitation
letters to be sent to all of his or her living full siblings. In
the letter, siblings are asked to indicate whether they are
interested in participating in SWISS by completing the
contact information section and sending it to the Clinical
Coordinating Center. The Center assigns SWISS numbers
to all siblings who provide contact information.
Phase II. Verifying Concordance and Discordance
The goal of Phase II is to confirm that phenotyping of sib-
lings is accurate.
Discordance is confirmed in Phase IIA. The Clinical Coor-
dinating Center contacts potentially discordant siblings
who provide contact information, obtains verbal consent
for a brief telephone interview, administers the QVSFS
(Table 1), and obtains a standardized medical history in a
structured telephone interview. Siblings who give negative
answers to the QVSFS medical history items but who give
a positive response to 1 or more of the review-of-symp-
toms items are advised to inform their primary care phy-
sician of their symptoms so that they can be evaluated
accordingly. Siblings who respond positively to QVSFS
item 1 advance to Phase IIB. If all of the QVSFS items are
negative, the patient is considered a verified discordant
sibling. The discordant sibling CRFs are completed during
the telephone interview, and the Clinical Coordinating
Center sends 2 copies of the Informed Consent Form
(ICF) to the verified discordant sibling, who returns 1
signed copy to the Center and retains 1 copy. Verified dis-
cordant siblings advance to Phase III of the study.
Concordance is confirmed in Phase IIB. The Clinical Co-
ordinating Center sends potentially concordant siblings a
Request for Medical Records Form (RMRF) and 2 copies of
the informed consent form to sign, date, and return. The
RMRF is a slightly modified study-specific version of the
official form used by Mayo Clinic for routine patient care.
Subjects return 1 copy of the signed form in a pre-ad-
dressed, postage-paid envelope provided with the original
form and retain the second copy. The Clinical Coordinat-
ing Center uses the signed form to request medical records
pertaining to the sibling index stroke. The Center con-
structs a file of medical records in a standardized, subdi-
vided sequence (hospital admission notes and discharge
summaries; neurologic consultation notes; reports of
computed tomographic and magnetic resonance imaging
of the head; reports of imaging of the heart by transthorac-
ic and transesophageal echocardiography; copies of elec-
trocardiograms; reports of imaging of cervicocephalic
vasculature by angiography using conventional, comput-
ed tomographic, or magnetic resonance techniques or by
ultrasonography; and reports of blood work).
The Clinical Coordinating Center submits completed files
on potentially concordant siblings to the SVC on a weekly
basis. A neurologist member of the SVC reviews the files
Table 2: Summary of Study Procedures
Phase I – Enrolling probands and recruiting siblings
Study neurologist identifies patient who meets criteria for SWISS.
Proband gives written informed consent and receives study invitation 
letters to give to siblings.
Interested siblings send contact information to Clinical Coordinating 
Center.
Phase IIA – Verifying discordance
Clinical Coordinating Center staff conducts structured telephone 
interview with presumed discordant sibling to verify absence of 
stroke (discordance) and sends informed consent form to verifed dis-
cordant siblings.
Verified discordant sibling sends signed consent form to Clinical 
Coordinating Center.
Phase IIB – Verifying concordance
Clinical Coordinating Center sends request forms for medical 
records and informed consent forms to presumed concordant sib-
lings.
Clinical Coordinating Center uses returned, signed forms to request 
medical records.
Stroke Verification Committee reviews medical records to verify 
stroke diagnosis (concordance).
Phase III – Acquiring blood for genetic analysis
Home health agency phlebotomist visits homes of proband, verified 
concordant sibling, and (if applicable) verified discordant sibling to 
obtain blood samples.
Home health agency forwards blood samples to DNA Bank.
Phase IV – Genome-wide screen
DNA Bank stores blood samples and notifies Genetics Laboratory 
when samples from 300 concordant sibling pairs have been collected.
Genetics Laboratory performs genome-wide screen.BMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/1
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and attempts to confirm the diagnosis of ischemic stroke,
using a standard stroke work-up checklist to assist with
and document a systematic review of the medical records.
The SVC may instruct the Clinical Coordinating Center to
secure additional medical records if the initial set fails to
provide sufficient evidence to confirm the diagnosis of
ischemic stroke. If the SVC neurologist cannot confirm the
diagnosis of stroke, the potentially concordant sibling
does not advance in the study. If concordance is con-
firmed, the SVC neurologist classifies the TOAST stroke
subtype, completes the CRFs for the concordant sibling,
and forwards the forms to the Clinical Coordinating Cent-
er.
Although as many as 10% of the concordant siblings in
SWISS may have a history of 2 or more strokes, the SVC
confirms the diagnosis and classifies the subtype of
ischemic stroke only for the most recent stroke for which
there are records sufficient to confirm the diagnosis (the
sibling index stroke). The verified concordant sibling then
advances to Phase III.
Phase III. Acquiring Blood for Genetic Analysis
Blood samples are taken only when a study pedigree is
complete, i.e., clinical data and ICF are available from 1
proband and at least 1 verified concordant sibling, with or
without 1 verified discordant sibling. If the diagnosis of
ischemic stroke cannot be verified for any sibling of a
proband, the clinical data from that proband are saved,
but no blood samples are collected. When a pedigree is
complete, the Clinical Coordinating Center instructs the
home health agency to collect blood samples from all
pedigree members. A phlebotomist from the home health
agency visits the subjects at their homes, obtains a blood
sample, and ships it to the DNA Bank.
Phase IV. Genome-wide Scan
The DNA Bank creates cell lines and notifies the Genetics
Laboratory when 300 concordant sibling pair specimens
are ready for analysis. The Genetics Laboratory then per-
forms the genome-wide scan.
Measures of outcome
The primary outcome is the degree of linkage between the
stroke phenotype and genetic markers as measured by the
proportion of alleles shared by concordant sibling pairs
(accumulated over all pairs at each marker).
Clinical database
For each proband, we collect name, date of birth, gender,
race, home address, home phone number, e-mail address,
and alternative contact information. We record the enroll-
ing investigator's study number and the study center
number to assure accurate attribution of efforts and to
make it possible to verify entries in CRFs with source doc-
uments. Data are collected on stroke risk factors and med-
ical history, date of onset of stroke symptoms, TOAST
stroke subtype, and the total number of living full sib-
lings.
The following information is collected on all living full
siblings who return sibling response letters: name, date of
birth, gender, name of the proband they are related to,
twin status, home address, home phone number, e-mail
address, alternative contact information, and standard-
ized risk factor and medical history.
In addition, for each concordant sibling, we record date of
review of outside medical records, a stroke work-up check-
list addressing medical reports reviewed by the physician
member of the SVC who confirms stroke concordance,
date of onset of index stroke (and of first stroke, if sibling
had more than one), TOAST subtype of index stroke, and
responses to all items contained in the QVSFS. For dis-
cordant siblings, we record responses to all items con-
tained in the QVSFS.
Genotyping
Local centers receive blood shipping kits, including a Va-
cutainer for blood, by mail at the start of SWISS, and the
Clinical Coordinating Center will restock the supply on a
continuing basis. Used kits are shipped overnight to the
DNA Bank for processing. Lymphoblastoid cell lines will
be generated from peripheral blood leukocytes and DNA
extracted using routine methods. DNA analysis will begin
after the 300th concordant sibling pair is enrolled, which
we anticipate to be at the end of year 4. At that time, the
DNA Bank will ship at least 50 µg of DNA to the Genetics
Laboratory.
At the Genetics Laboratory, the DNA will be plated onto
384-well plates for marker genotyping. The ABI Genescan/
Genotyper system will be employed in semiautomated
fluorescent genotyping, comparing fragment sizes to an
internal standard of CEPH DNA. An ABI377 with 96 wells
generates the marker data. All genotypes will be scored
blind to phenotype. Two hundred thirty-seven microsatel-
lite markers, obtained from Genethon, CHLC, and GDB
(106 di-, 21 tri-, and 110 tetranucleotides), will be typed
in all sibling pairs. These 237 markers have been sorted
into 30 panels. We will run 92 samples per gel (with 4
lanes for controls); estimating ~920 samples at 30 panels,
300 gels will be needed. Allowing for reruns and data loss,
we estimate that 400 gels will be required to complete this
task and extract greater than 90% of the genetic data. The
average distance between adjacent markers in this panel
series is 16.3 cM (1–40 cM). Average heterozygosity will
be calculated. The CRI-MAP program will determine inter-
marker distances and will also be used to form the study-
specific genetic map. A genotype database (Megabase)BMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/1
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will be used to check the binning of alleles, convert allele
sizes to whole numbers, and (where possible) to test for
non-Mendelian inheritance. Megabase will store all rele-
vant genotypic/phenotypic data and produce all files
needed for statistical analysis.
Cell lines
We regard banking of samples to be a key element of this
study. Collection of clinical samples is expensive and time
consuming, and it is probable that progress in identifying
genes involved in stroke will be incremental. For genes of
smaller effect, very large sample sizes are likely to be need-
ed. Having these resources available will ensure that fu-
ture work can build effectively on the work we present
here. Epstein-Barr virus-transformed lymphoblastoid cell
lines will be used.
Statistical methods
For the concordant sibling pair design, the proportion of
alleles shared by the concordant sibling pairs (accumulat-
ed over all pairs at that marker) is the statistic that deter-
mines evidence for linkage between the stroke phenotype
and the genetic marker. If only concordant sibling pairs
are collected, a maximum of only 4 alleles can be identi-
fied. The third (discordant) sibling is collected for purpos-
es of determining potential nonpaternities in a sibship
(more than 4 alleles) and for better estimating the propor-
tion of alleles shared that are identical by state (in the ab-
sence of parents).
Traditional applications of gene mapping have used fam-
ilies in which the trait (disease) is transmitted in a clearly
Mendelian fashion. For more complex traits, the inherit-
ance pattern does not fit a single-gene model, and meth-
ods that assume a genetic model may provide erroneous
results [59]. Ischemic stroke clearly demonstrates familial
aggregation, yet no single-gene model of transmission is
consistent with the family data. In this project, we propose
to use model-independent (relative pair) analysis, a meth-
od that is designed to detect linkage without the specifica-
tion of an underlying genetic model and that is robust to
contributions by environmental variation. The methods
of analysis for determination of risk factor loci will mainly
use the SPLINK and MAPMAKER/SIBS programs [60,61].
Estimates of power to detect linkage
For concordant sibling pair studies, Risch [62,63] demon-
strated that the fraction Kr/Kp, defined as the risk ratio λ r
for a type-R relative, can be used to model the probable
modes of transmission for a complex disease. Thus, under
a given model, the value of λ r should decrease in a model-
specific manner for each decreasing degree of unilineal re-
lationship, and this expected value can then be contrasted
with recurrence risks obtained from a set of relatives
(monozygotic twins, dizygotic twins, siblings, offspring,
second-degree relatives, etc.). For a single-locus model,
therefore, the value of (λ r-1) should decrease by a factor of
2, and a multiplicative model predicts risk on the basis of
the product of the individual factors.
Risch [63] extended the approach of Suarez et al [64] to
include any relative pair. On the basis of this formulation,
the power to detect linkage can be obtained for relative
(sibling) pairs. For concordant sibling pairs, assuming
that the candidate locus is near a stroke susceptibility lo-
cus (θ  > 0), power depends upon λ s (sibling recurrence
risk) and λ o (offspring recurrence risk). If there is little
dominance effect, then λ s = λ o, and hence the power can
be computed on the basis of sibling recurrence risk. For
other pairs of relatives, Risch [63] has shown that the sin-
gle parameter λ o is sufficient to specify power (and θ , if θ
> 0). The recurrence risk data in relatives are sparse for
stroke. Data from Framingham suggest that a reasonable
estimate of λ s for stroke may range from 2 to 5.
We assume that the genetic markers used have polymor-
phic information content (PIC) equivalent to that of an
equiprobable 4-allele system, yielding a PIC of about
70%. The sample size required to determine a given power
is inversely proportional to the PIC of the markers; thus, a
sample of 300 concordant sibling pairs genotyped at a
marker with PIC of 70% would be equivalent to a fully in-
formative marker typed on 210 concordant pairs. In our
consideration of power, therefore, we consider a marker
with incomplete information, and the initial analyses will
comprise pairwise analyses. Application of multipoint
(interval) mapping methods will further increase power
[65]. Formal analyses with MAPMAKER/SIBS or Gene-
Hunter will add further power by means of the multipoint
method. Using this approach, we have estimated power
for a set of 300 sibling pairs concordant for stroke (equiv-
alent to 210 pairs with fully informative markers but with-
out parents). With these estimates, we should have ample
power to detect linkage between a marker and a moderate-
ly strong susceptibility locus, especially for locus-specific
sib risks greater than 3.
For a homogeneous single disease susceptibility locus, the
power to detect linkage with our expected 300 concordant
sibling pairs generally approaches 100% (Table 3). If
stroke susceptibility is attributable to several loci, the risk
becomes dependent upon the nature of the contributions
(additive or epistatic), and the loci are more difficult to
identify. Recent efforts utilizing analysis of genome scan
data conditional on the evidence for linkage of a major
susceptibility factor show promise [66]. With 300 con-
cordant sibling pairs, we have over 70% power to detect
linkage with a genome-wide significance of P = 0.00022
and locus-specific risk of λ s = 1.6. As was demonstrated in
the discordant sibling-pair analyses, we may have sub-BMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/1
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stantial power to detect linkage using a complementary
analytic approach, so that the addition of even 100 dis-
cordant siblings to the concordant sibling pairs may pro-
vide additional insight on linkage.
Discussion
It is clearly of importance to define genetic risk factor loci
for stroke. Defining such loci should eventually enable us
to determine prospectively those who are at high risk for
the disease and to counsel and treat them based on this
knowledge: in addition, these risk factor loci may help in
the identification of new drug targets for effective treat-
ment of this prevalent disease. However, special safe-
guards must be in place to protect the rights of subjects
involved in genetic research. If genetic information is im-
properly safeguarded, misuse could adversely influence
insurability [67] and employability [68] of subjects and
could stigmatize individuals or groups [69]. For this
study, we have adopted many of the practical suggestions
of Merz and colleagues [70] regarding the ethical use of
human tissue. For linking purposes, we use special study-
specific codes, rather than medical record numbers, Social
Security numbers, or an easily decoded combination of
initials and birth dates. Access to linking files is restricted
to an as-needed basis only, and the files are deleted when
they are no longer needed. The study mandates a strictly
unidirectional flow of information. This means that clini-
cal data are used for research purposes, but research data
are not used for clinical purposes. This restriction on the
use of the SWISS data set is based on our recognition that
unique clinical obligations accompany the provision of
predictive genetic test results to individual patients [71].
Recently, there has been intense debate in the United
States at the federal level over the privacy rights of pedi-
gree members with respect to genetic research. For this
study, we have adopted the position that every member of
a pedigree has the right to refuse to have personal infor-
mation such as name, address, and medical history re-
corded in a research database. This right cannot be waived
by other members of the pedigree [72]. Therefore,
probands or their noninvestigator surrogates invite other
family members to participate. Siblings who are interested
in participating voluntarily provide investigators with
their name, address, and telephone number.
Identifying the genetic basis of diseases with complex
modes of inheritance is a daunting task, and it is likely
that a variety of approaches will be necessary to elucidate
the genetic basis of human stroke. Genomics has been ap-
plied to animal models of stroke and yielded discoveries
about loci that correlate with stroke risk. For example, Ru-
battu and colleagues [73] identified 3 major quantitative
trait loci in the F2 cross of stroke-prone and spontaneous-
ly hypertensive rats. Conducting adequately powered ge-
nomics studies of stroke in humans is considerably more
challenging.
The central approach this study takes is to identify areas of
the genome that siblings affected by stroke share more of-
ten than one would expect by chance. The strength of this
approach is its theoretical robustness, because the meth-
ods make relatively few assumptions about either the ge-
netic architecture of the population in which the disease
is studied or about the disease risk. The weaknesses of the
approach are its relative lack of power and the low resolu-
tion of the linkage peaks identified. In addition, the logis-
tical problem of obtaining DNA samples from clinically
well-characterized members of a cohort of stroke pedi-
grees can be a daunting task.
Table 3: Power to Detect Linkage as a Function of λ S, θ , and Type I Error Rate (α )
α
0.10 0.05 0.0001
λ S θ  = 0.050 θ  = 0.075 θ  = 0.050 θ  = 0.075 θ  = 0.050 θ  = 0.075
2.0 0.98 0.95 0.96 0.90 0.40 0.24
2.5 1.00 0.99 1.00 0.98 0.74 0.52
3.0 1.00 1.00 1.00 1.00 0.92 0.73
4.0 1.00 1.00 1.00 1.00 1.00 0.92
α , type I error; θ , recombination fraction (which is related to the distance between the marker and trait loci); λ S, locus-specific relative risk to sib-
lings.BMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/1
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Although our primary analytic methods will focus on the
concordant pair design, we will also use a complementary
and related approach, the discordant sibling pair method.
This method essentially searches for areas of the genome
that are shared less often than one would expect by
chance. Discordant siblings are generally easier to collect
because they are more frequent than concordant siblings
in a disease such as stroke. As demonstrated in the case of
diabetic nephropathy [74], the discordant sibling pair ap-
proach can have greater power than the concordant sib-
ling pair approach in certain situations. However, the
discordant sibling pair approach is often less efficient
than the concordant sibling method because of the uncer-
tainty of the final diagnostic status of the unaffected sib-
ling. Discordant siblings might have subclinical
(radiographic) stroke or be discordant only because of
their relative youth. Furthermore, resource limitations in
this study prevent the collection of blood from more than
1 discordant sibling for each concordant pair.
An alternative design to one using affected relative pairs is
that of genome-wide association in subjects with ischemic
stroke (cases) ascertained without respect to family histo-
ry compared with nonstroke controls for frequency of nu-
merous, densely spaced genetic markers (single
nucleotide polymorphisms or SNPs). Although the cases
and controls are collected more easily than concordant
sibling pairs, this approach also has limitations. First, the
case-control approach is not robust to differential envi-
ronmental contribution, so that heterogeneity between
case and control exposure could result in spurious associ-
ation. Second, unlike the concordant sibling pair ap-
proach, controls are "unaffected" only at time of
collection. The control sample actually represents a mix-
ture of subjects who will never have an ischemic stroke
and those who will eventually have an ischemic stroke.
Thus, true associations can be missed due to misclassiflca-
tion. Third, the number of subjects to be collected to pro-
vide genome-wide significance for an association study
remains large, given the number of SNPs to be genotyped
across the genome to provide 10 kb to 50 kb spacing. To
address the "multiple comparisons" concern with thou-
sands of SNPs, 10,000 to 20,000 cases and controls would
need to be studied.
Association studies in a case/control framework have a
long history in stroke etiology research. However, these
studies have been problematic because until now they
have only allowed testing for the known candidates, and
they have been plagued by false positives. With the com-
pletion of the First Draft of the Human Genome, and the
identification of haplotype maps, it may be that this ap-
proach can be adapted to a whole genome association
strategy using prudently positioned SNPs and DNA sam-
ples banked in SWISS.
Much of the theoretical challenge of finding genetic risk
factors comes from the heterogeneity of the stroke pheno-
type. In SWISS we are studying the ultimate phenotype of
ischemic stroke. An alternative approach would be to
study an intermediate phenotype, such as carotid athero-
sclerosis, with the hope that alleles underlying this pheno-
type play a role in the etiology of the stroke itself. Shifting
the object of investigation from ischemic stroke to carotid
atherosclerosis would decrease the numbers of subjects
needed. Another advantage is that carotid atherosclerosis
can be treated as a quantitative trait. However, using carot-
id atherosclerosis as an intermediate phenotype for
ischemic stroke also has limitations. Perhaps the most im-
portant difficulty is that high-grade carotid atherosclerosis
is not a prerequisite intermediate phenotype in most pa-
tients with ischemic stroke. The large-artery atherosclerot-
ic subtype of ischemic stroke accounted for only 13% of
all ischemic strokes in a recent population-based study in
Bavaria, Germany [75]. Similarly, the large-artery athero-
sclerotic subtype accounted for only 16% of all ischemic
strokes in a population-based study in Rochester, Minne-
sota [76]. In addition to not being a mandatory interme-
diate phenotype in the biological process leading to
ischemic stroke, carotid atherosclerosis is itself a complex
phenotype. Degree of stenosis is not the only factor affect-
ing symptomatology of an atherosclerotic carotid artery
[77], and important differences between intracranial and
cervical arteries in the genetics of atherosclerosis may go
unrecognized if the object of study is cervical carotid
atherosclerosis [78].
Our study directly addresses the heterogeneity of the
ischemic stroke phenotype through the study-wide use of
a standardized, validated, and widely accepted system of
classifying ischemic strokes based on presumed etiology.
The process of certification minimizes variation among
local center physician investigators in assigning TOAST
stroke subtype to probands. The process of central adjudi-
cation minimizes the variation in assigning TOAST sub-
type to concordant siblings. Although we recognize that it
may be of value for future studies to define concordance
for phenotype by ischemic stroke subtype, we have cho-
sen to regard that approach as exploratory at this stage.
One way of dealing with the logistic challenges inherent
in genetic studies is to collect cases from an isolated pop-
ulation, such as Iceland [79]. However this approach re-
quires an integrated health care database not easily
applicable within the US health care model, and the re-
quired community consent is probably not possible with-
in the US legal/ethical framework [80,81]. Logistic
difficulties have been mitigated by the steady evolution in
multicentered clinical trials that has occurred in the field
of stroke research [82]. SWISS is designed as a multicenter
clinical trial, and the use of a nationwide home healthBMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/1
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agency for phlebotomy service enables us to obtain blood
from siblings living far away from one another. Whereas a
requirement that study subjects travel to a local study
center could result in failure to enroll patients for logistic
reasons, a home health agency can obtain blood from
study subjects rendered homebound by stroke or other
ailments. Thus, it is hoped that this study design will effi-
ciently assemble a cohort of ischemic stroke pedigrees
without invoking community consent or using "cold-call-
ing" of pedigree members.
In conclusion, we believe that the DNA samples collected
in this study will not only be of use in defining regions of
the genome in which stroke genes reside. They may also
be of use in testing for allelic association of candidate
genes and regions by SNPs, because alleles that predispose
to disease should have a higher allele frequency in siblings
who share chromosomal regions than in siblings who do
not. Because the cell lines are banked, we hope to facilitate
the identification of stroke risk factor genes both directly
by ourselves and by others.
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